STOCK TITAN

[Form 4] Moleculin Biotech, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Donald H. Picker, Chief Science Officer of Moleculin Biotech (MBRX), reported multiple transactions involving restricted stock units (RSUs) and common stock:

  • On June 20, 2025, converted 1,078 RSUs to common stock and had 263 shares withheld for tax purposes at $0.267 per share, resulting in 8,816 directly owned shares
  • On June 22, 2025, converted 1,766 RSUs to common stock and had 430 shares withheld for tax purposes at $0.267 per share, resulting in 10,152 directly owned shares

These transactions stem from two RSU grants: 4,312 units granted on June 20, 2022, and 7,063 units granted on June 22, 2023, both vesting in four equal annual installments. Following these transactions, Picker maintains direct ownership of 104,258 RSUs.

Donald H. Picker, Chief Science Officer di Moleculin Biotech (MBRX), ha effettuato diverse operazioni riguardanti unità azionarie vincolate (RSU) e azioni ordinarie:

  • Il 20 giugno 2025, ha convertito 1.078 RSU in azioni ordinarie, trattenendo 263 azioni per scopi fiscali al prezzo di 0,267 dollari per azione, portando il totale delle azioni direttamente possedute a 8.816
  • Il 22 giugno 2025, ha convertito 1.766 RSU in azioni ordinarie, trattenendo 430 azioni per scopi fiscali al prezzo di 0,267 dollari per azione, portando il totale delle azioni direttamente possedute a 10.152

Queste operazioni derivano da due assegnazioni di RSU: 4.312 unità concesse il 20 giugno 2022 e 7.063 unità concesse il 22 giugno 2023, entrambe con maturazione in quattro rate annuali uguali. Dopo queste transazioni, Picker detiene direttamente 104.258 RSU.

Donald H. Picker, Director Científico de Moleculin Biotech (MBRX), informó sobre varias transacciones relacionadas con unidades restringidas de acciones (RSU) y acciones comunes:

  • El 20 de junio de 2025, convirtió 1,078 RSU en acciones comunes y retuvo 263 acciones para impuestos a $0.267 por acción, resultando en 8,816 acciones de propiedad directa
  • El 22 de junio de 2025, convirtió 1,766 RSU en acciones comunes y retuvo 430 acciones para impuestos a $0.267 por acción, resultando en 10,152 acciones de propiedad directa

Estas transacciones provienen de dos concesiones de RSU: 4,312 unidades otorgadas el 20 de junio de 2022 y 7,063 unidades otorgadas el 22 de junio de 2023, ambas con adquisición en cuatro cuotas anuales iguales. Tras estas operaciones, Picker mantiene la propiedad directa de 104,258 RSU.

도널드 H. 피커, Moleculin Biotech(MBRX)의 최고과학책임자는 제한 주식 단위(RSU)와 보통주 관련 여러 거래를 보고했습니다:

  • 2025년 6월 20일, 1,078 RSU를 보통주로 전환하고 주당 $0.267의 세금 목적으로 263주를 원천징수하여 직접 보유 주식 수가 8,816주가 되었습니다
  • 2025년 6월 22일, 1,766 RSU를 보통주로 전환하고 주당 $0.267의 세금 목적으로 430주를 원천징수하여 직접 보유 주식 수가 10,152주가 되었습니다

이 거래들은 2022년 6월 20일에 부여된 4,312 단위와 2023년 6월 22일에 부여된 7,063 단위 두 건의 RSU 부여에서 비롯되었으며, 모두 4년간 매년 동일한 비율로 권리 취득됩니다. 이 거래 이후 피커는 직접 104,258 RSU를 보유하고 있습니다.

Donald H. Picker, Directeur scientifique de Moleculin Biotech (MBRX), a déclaré plusieurs transactions impliquant des unités d'actions restreintes (RSU) et des actions ordinaires :

  • Le 20 juin 2025, il a converti 1 078 RSU en actions ordinaires et a retenu 263 actions à des fins fiscales au prix de 0,267 $ par action, ce qui porte le nombre d'actions détenues directement à 8 816
  • Le 22 juin 2025, il a converti 1 766 RSU en actions ordinaires et a retenu 430 actions à des fins fiscales au prix de 0,267 $ par action, ce qui porte le nombre d'actions détenues directement à 10 152

Ces transactions proviennent de deux attributions de RSU : 4 312 unités accordées le 20 juin 2022 et 7 063 unités accordées le 22 juin 2023, toutes deux acquises en quatre versements annuels égaux. Après ces transactions, Picker détient directement 104 258 RSU.

Donald H. Picker, Chief Science Officer von Moleculin Biotech (MBRX), meldete mehrere Transaktionen mit Restricted Stock Units (RSUs) und Stammaktien:

  • Am 20. Juni 2025 wurden 1.078 RSUs in Stammaktien umgewandelt, wobei 263 Aktien für Steuerzwecke zum Preis von 0,267 USD pro Aktie einbehalten wurden, was zu 8.816 direkt gehaltenen Aktien führte
  • Am 22. Juni 2025 wurden 1.766 RSUs in Stammaktien umgewandelt, wobei 430 Aktien für Steuerzwecke zum Preis von 0,267 USD pro Aktie einbehalten wurden, was zu 10.152 direkt gehaltenen Aktien führte

Diese Transaktionen stammen aus zwei RSU-Zuweisungen: 4.312 Einheiten, die am 20. Juni 2022 gewährt wurden, und 7.063 Einheiten, die am 22. Juni 2023 gewährt wurden, beide mit vier gleichmäßigen jährlichen Vesting-Raten. Nach diesen Transaktionen hält Picker direkt 104.258 RSUs.

Positive
  • None.
Negative
  • None.

Donald H. Picker, Chief Science Officer di Moleculin Biotech (MBRX), ha effettuato diverse operazioni riguardanti unità azionarie vincolate (RSU) e azioni ordinarie:

  • Il 20 giugno 2025, ha convertito 1.078 RSU in azioni ordinarie, trattenendo 263 azioni per scopi fiscali al prezzo di 0,267 dollari per azione, portando il totale delle azioni direttamente possedute a 8.816
  • Il 22 giugno 2025, ha convertito 1.766 RSU in azioni ordinarie, trattenendo 430 azioni per scopi fiscali al prezzo di 0,267 dollari per azione, portando il totale delle azioni direttamente possedute a 10.152

Queste operazioni derivano da due assegnazioni di RSU: 4.312 unità concesse il 20 giugno 2022 e 7.063 unità concesse il 22 giugno 2023, entrambe con maturazione in quattro rate annuali uguali. Dopo queste transazioni, Picker detiene direttamente 104.258 RSU.

Donald H. Picker, Director Científico de Moleculin Biotech (MBRX), informó sobre varias transacciones relacionadas con unidades restringidas de acciones (RSU) y acciones comunes:

  • El 20 de junio de 2025, convirtió 1,078 RSU en acciones comunes y retuvo 263 acciones para impuestos a $0.267 por acción, resultando en 8,816 acciones de propiedad directa
  • El 22 de junio de 2025, convirtió 1,766 RSU en acciones comunes y retuvo 430 acciones para impuestos a $0.267 por acción, resultando en 10,152 acciones de propiedad directa

Estas transacciones provienen de dos concesiones de RSU: 4,312 unidades otorgadas el 20 de junio de 2022 y 7,063 unidades otorgadas el 22 de junio de 2023, ambas con adquisición en cuatro cuotas anuales iguales. Tras estas operaciones, Picker mantiene la propiedad directa de 104,258 RSU.

도널드 H. 피커, Moleculin Biotech(MBRX)의 최고과학책임자는 제한 주식 단위(RSU)와 보통주 관련 여러 거래를 보고했습니다:

  • 2025년 6월 20일, 1,078 RSU를 보통주로 전환하고 주당 $0.267의 세금 목적으로 263주를 원천징수하여 직접 보유 주식 수가 8,816주가 되었습니다
  • 2025년 6월 22일, 1,766 RSU를 보통주로 전환하고 주당 $0.267의 세금 목적으로 430주를 원천징수하여 직접 보유 주식 수가 10,152주가 되었습니다

이 거래들은 2022년 6월 20일에 부여된 4,312 단위와 2023년 6월 22일에 부여된 7,063 단위 두 건의 RSU 부여에서 비롯되었으며, 모두 4년간 매년 동일한 비율로 권리 취득됩니다. 이 거래 이후 피커는 직접 104,258 RSU를 보유하고 있습니다.

Donald H. Picker, Directeur scientifique de Moleculin Biotech (MBRX), a déclaré plusieurs transactions impliquant des unités d'actions restreintes (RSU) et des actions ordinaires :

  • Le 20 juin 2025, il a converti 1 078 RSU en actions ordinaires et a retenu 263 actions à des fins fiscales au prix de 0,267 $ par action, ce qui porte le nombre d'actions détenues directement à 8 816
  • Le 22 juin 2025, il a converti 1 766 RSU en actions ordinaires et a retenu 430 actions à des fins fiscales au prix de 0,267 $ par action, ce qui porte le nombre d'actions détenues directement à 10 152

Ces transactions proviennent de deux attributions de RSU : 4 312 unités accordées le 20 juin 2022 et 7 063 unités accordées le 22 juin 2023, toutes deux acquises en quatre versements annuels égaux. Après ces transactions, Picker détient directement 104 258 RSU.

Donald H. Picker, Chief Science Officer von Moleculin Biotech (MBRX), meldete mehrere Transaktionen mit Restricted Stock Units (RSUs) und Stammaktien:

  • Am 20. Juni 2025 wurden 1.078 RSUs in Stammaktien umgewandelt, wobei 263 Aktien für Steuerzwecke zum Preis von 0,267 USD pro Aktie einbehalten wurden, was zu 8.816 direkt gehaltenen Aktien führte
  • Am 22. Juni 2025 wurden 1.766 RSUs in Stammaktien umgewandelt, wobei 430 Aktien für Steuerzwecke zum Preis von 0,267 USD pro Aktie einbehalten wurden, was zu 10.152 direkt gehaltenen Aktien führte

Diese Transaktionen stammen aus zwei RSU-Zuweisungen: 4.312 Einheiten, die am 20. Juni 2022 gewährt wurden, und 7.063 Einheiten, die am 22. Juni 2023 gewährt wurden, beide mit vier gleichmäßigen jährlichen Vesting-Raten. Nach diesen Transaktionen hält Picker direkt 104.258 RSUs.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PICKER DONALD H

(Last) (First) (Middle)
C/O MOLECULIN BIOTECH, INC.
5300 MEMORIAL DR., SUITE 950

(Street)
HOUSTON TX 77007

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Moleculin Biotech, Inc. [ MBRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Science Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 M 1,078 A (1) 9,079 D
Common Stock 06/20/2025 F 263(2) D $0.267 8,816 D
Common Stock 06/22/2025 M 1,766 A (1) 10,582 D
Common Stock 06/22/2025 F 430(2) D $0.267 10,152 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 06/20/2025 M 1,078 (3) (3) Common Stock 1,078 $0 106,024 D
Restricted Stock Units (1) 06/22/2025 M 1,766 (4) (4) Common Stock 1,766 $0 104,258 D
Explanation of Responses:
1. Restricted stock units convert into common stock on a one-for-one basis.
2. Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
3. On June 20, 2022, the reporting person was granted 4,312 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
4. On June 22, 2023, the reporting person was granted 7,063 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
/s/ Jonathan P. Foster 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MBRX shares did Chief Science Officer Donald Picker acquire on June 20, 2025?

Donald Picker acquired 1,078 shares of MBRX common stock on June 20, 2025 through the conversion of restricted stock units (RSUs). However, 263 shares were withheld for tax purposes, resulting in a net acquisition of 815 shares.

What was the vesting schedule for MBRX's RSU grant to Donald Picker in June 2022?

The RSU grant made on June 20, 2022, consisted of 4,312 restricted stock units that vest in four equal annual installments beginning on the first anniversary of the grant date.

How many MBRX restricted stock units does Donald Picker own after the June 22, 2025 transaction?

Following the reported transactions, Donald Picker owns 104,258 restricted stock units of MBRX directly, as shown in Table II of the Form 4 filing.

What is the total number of MBRX common shares Donald Picker owns after all reported transactions?

After all reported transactions on June 20 and June 22, 2025, Donald Picker directly owns 10,152 shares of MBRX common stock, as indicated in the final entry of Table I.

At what price were MBRX shares withheld for tax purposes in the June 2025 transactions?

The shares withheld for tax purposes were valued at $0.267 per share for both the June 20 and June 22, 2025 transactions.
Moleculin Biotec

NASDAQ:MBRX

MBRX Rankings

MBRX Latest News

MBRX Latest SEC Filings

MBRX Stock Data

3.87M
23.03M
0.75%
3.49%
9.01%
Biotechnology
Pharmaceutical Preparations
Link
United States
HOUSTON